Company ProfilePremium

Pak Fah Yeow International Limited

Company Profile Analysis

Ticker: 0239.HK白花油國際有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Pak Fah Yeow International Limited - Company showcase

Year Founded & Workforce

1927

100 Employees

Pak Fah Yeow International Limited logo

Pak Fah Yeow International Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Pak Fah Yeow International Limited Overview

MetricFY2021FY2022FY2023FY2024FY2025
Employees at year end (number)8795102106100
Staff costs (HK$ M)34.634.644.043.345.6
Revenue per employee (HK$ M)1.611.552.542.232.14

Source: Annual results announcements FY2022, FY2024, FY2025 (Employees and Remuneration Policies; Consolidated Statement of Comprehensive Income). Revenue per employee is analyst-derived.

Pak Fah Yeow International is a family-controlled Hong Kong heritage consumer-health company whose economic engine is a single nearly century-old brand: Hoe Hin White Flower Embrocation (白花油, "Pak Fah Yeow"), a eucalyptus-, lavender-, menthol- and methyl salicylate-based medicated oil used for headaches, congestion, motion sickness, muscular pain and insect bites. Healthcare generated 92.3% of FY2025 revenue at a segment margin near 59%, giving the group exceptionally high-margin, asset-light-like economics despite owning its manufacturing. Around this brand sit two capital-allocation businesses — an HK$228 million investment-property portfolio across Hong Kong, Singapore and the United Kingdom, and a treasury book of roughly HK$350 million in cash and securities. The group is effectively debt-free, pays out 60–80% of earnings, and trades near book value. Its strategic challenge is demographic and channel-related: renewing a legacy brand for younger, online-first Chinese consumers while managing heavy dependence on Greater China and on five distributors.


What the company does

Pak Fah Yeow International is an investment holding company organised into three reportable operating segments, as defined in note 2 of the FY2025 annual results announcement:

  1. Healthcare — manufacture and sale of Hoe Hin brand of products.

  2. Property Investments — rental of investment properties in Hong Kong (office and residential), Singapore (industrial) and the United Kingdom (retail/residential).

  3. Treasury Investments — bank deposits, equity and debt securities, mutual funds and dual-currency investments.

Company's own description

In its annual reports, the company describes itself as principally engaged in the manufacture, marketing and distribution of healthcare products under its Hoe Hin brand, centred on the medicated oil known as Pak Fah Yeow, with manufacturing carried out by its subsidiary Hoe Hin Pak Fah Yeow Manufactory Limited, and with supplementary property and treasury investment activities (Annual Report 2022 and 2023, "About Us"). The 2022 report described the oil as having been manufactured for over 95 years and sold in Hong Kong, Macau, Mainland China, Southeast Asia and western countries.

Revenue model

Revenue type (FY2025)HKD Mn% of revenueNature
Sale of Hoe Hin products — fixed price75.235.2Product sales (HKFRS 15)
Sale of Hoe Hin products — variable price122.157.1Product sales with rebates/discounts to distributors (HKFRS 15)
Lease income (fixed lease payments)9.94.6Rental (HKFRS 16)
Interest income from bank deposits6.63.1Treasury
Total revenue213.9100.0—

Source: FY2025 Annual Results Announcement, note 3. The business is almost entirely a branded-product model; there is no subscription, licensing or service revenue of significance. The variable-price share of product revenue rose from 46.4% in FY2024 to 61.9% in FY2025, reflecting heavier use of distributor rebate and discount arrangements.

Value chain position

The group is vertically integrated from formulation to finished packaged product: it sources essential oils and actives (retail product listings state that most natural ingredients are imported from France, China and Australia to British Pharmacopoeia or Chinese Pharmacopoeia standards), manufactures and bottles in Hong Kong, and sells primarily to distributors and chain retailers. It does not operate its own retail stores. In Hong Kong its core channels are drug stores and major chain retailers (FY2025 MD&A); product listings confirm presence at Watsons and Mannings. In Mainland China, the company is building direct-to-consumer reach through Douyin and Xiaohongshu content marketing, KOL partnerships and cross-border e-commerce launched in 2025.

Customer types and concentration

MetricFY2021FY2022FY2023FY2024FY2025
Revenue from customers each above 10% of healthcare revenue (HK$ M)112.985.7133.8124.6147.0
Number of such customers64445
Share of healthcare segment revenue (%)84.961.554.657.374.5

Customers are predominantly distributors and retail chains. Concentration is high and rising:

Source: Annual results announcements FY2022, FY2024, FY2025 ("Information about major customers"). Percentages analyst-derived.

End-markets served

Over-the-counter (OTC) topical analgesic and traditional medicated oil category, primarily in Greater China (Hong Kong, Macau, Mainland China), Southeast Asia (notably the Philippines, Singapore, Thailand, Malaysia), and North America (United States, Canada), with minor sales elsewhere. The product is registered in Hong Kong as a proprietary Chinese medicine (Hong Kong Memory Project oral history).

Independent characterisation

Pak Fah Yeow is best understood as a single-brand heritage consumer-health franchise wrapped in a family holding company. The franchise earns segment margins of 59–64% and requires minimal capital expenditure (additions to non-current assets of only HK$0.4 million in FY2025). Surplus cash is not reinvested in growth M&A — management has repeatedly stated it has no plan for significant investment or acquisition of capital assets — but retained in deposits, securities and property, or distributed as special dividends. The result is a business whose reported earnings are distorted by non-cash property revaluations, whose balance sheet is over-capitalised (cash and securities equal roughly half of market capitalisation), and whose growth is driven by cyclical swings in Greater China demand rather than structural expansion. The 2023 border-reopening boom (healthcare revenue +75.8%) followed by a two-year normalisation illustrates the volatility.

Strategy

Stated strategic themes (paraphrased from FY2024 and FY2025 Chairman's Statements and H1 2026 MD&A)

  1. Digital transformation of China distribution: Shift resources toward e-commerce and online engagement in China to match consumer migration online; FY2024 disclosed that online contributed less than 3% of revenue, a gap management is explicitly trying to close.

  2. Content and KOL marketing: Increase advertising on Douyin and Xiaohongshu, collaborate with key opinion leaders, and enhance video content to rebuild brand visibility among younger consumers.

  3. Cross-border e-commerce: Launched in 2025 to diversify channels; management cautioned that these initiatives may take time to contribute meaningfully.

  4. Product portfolio extension: Planned launch of Hoe Hin White Flower Oil Roll-On and GoodDay essential oil to attract new consumer groups (H1 2026).

  5. Centenary brand campaign: Advertising and promotional campaigns prepared for the 100th anniversary (1927–2027).

  6. Southeast Asia brand building: Continued branding and promotion in the Philippines, Singapore and Thailand.

  7. Prudent asset management: Maintain occupancy and rental stability across the property portfolio amid Hong Kong vacancy pressure.

  8. Conservative treasury: Prioritise capital preservation while seeking reasonable risk-adjusted returns.

  9. Shareholder returns: Sustain regular plus special dividends; maintain a strong balance sheet and liquidity.

Initiatives announced in the last 24 months

InitiativeAnnouncedStatusTargets disclosed
Expanded online promotion and e-commerce focus in ChinaMar 2025 (FY2024 results)In progressNone quantified
Douyin / Xiaohongshu / KOL / video content programmeFY2025OngoingNone quantified
Cross-border e-commerce operationsLaunched during 2025Operating; early stage—
Advertising cost discipline (spend cut to HK$10.2 million from HK$14.1 million)FY2025Completed—
100th-anniversary advertising campaignsH1 2026Prepared, rolling out—
White Flower Oil Roll-OnAug 2026Planned launch—
GoodDay essential oilAug 2026Planned launch—
Thailand product licence renewal (with possible packaging changes)H1 2026 disclosureScheduled Q4 2026—
Generational transfer of Hexagan30 Jun 2026Completed—

ESG commitments

Energy-efficiency optimisation, a comprehensive recycling programme and improved packaging materials to reduce environmental footprint (FY2024 Chairman's Statement). Annual ESG reports published alongside annual reports. No quantified emissions targets were found.

Medium-term targets and guidance

Management does not issue quantitative financial targets or guidance. Qualitative H2 2026 outlook: cautious; China improvement encouraging but sustainability uncertain; deferred Philippine orders expected in H2; US orders expected to resume; full-year North American revenue expected to remain broadly stable.

Products & Services

The company does not publish a SKU-level catalogue, revenue by product, or prices in its filings. The list below is compiled from filings, regulatory product labels and retailer listings. All products sit within the Healthcare segment under the Hoe Hin brand.

Healthcare segment

Hoe Hin White Flower Embrocation (白花油 / Pak Fah Yeow) — flagship

  • Description: A blend of essential oils including eucalyptus oil and lavender oil, with methyl salicylate and menthol (retailer listings; some listings also cite camphor and wintergreen oil).

  • Indications (per retail labelling): relief of congestion associated with colds, dizziness and headache, temporary muscular pain, travel and motion sickness, and itching from insect bites; also used as a refreshing inhalant.

  • Regulatory status: registered in Hong Kong as a proprietary Chinese medicine (HK Memory oral history).

  • Formats: bottles in multiple sizes (e.g., 5ml listed in Malaysia; 10ml "#2" listed at Watsons Hong Kong at around HK$47).

  • Target customer: mass-market households in Greater China and Southeast Asia, historically skewing to older consumers; overseas Chinese diaspora in North America.

  • Launch year: 1927; formula kept largely unchanged to preserve its characteristic scent (HK Memory oral history).

  • Pricing model: retail price per bottle through distributors and chain retailers; distributor pricing increasingly on variable terms with rebates (61.9% of FY2025 product revenue was variable-price).

Hoe Hin White Flower Embrocation Floral-Scented "Fuzai 239" (福仔239)

  • Description: The traditional formula with added floral fragrance, developed to offer an alternative scent (retailer listing).

  • Indications: as for the flagship, including cooling and relief of summer heat.

  • Format: 10ml; listed at Mannings Hong Kong at around HK$46–50.

  • Target customer: consumers deterred by the pungency of traditional medicated oils; younger and female consumers.

  • Launch year: not publicly disclosed. The name echoes the company's stock code 239.

White Flower Strain Relief Pain Relieving Oil

  • Description: OTC external analgesic oil with camphor 10%, menthol 15% and methyl salicylate approximately 48–50% (US FDA OTC label records).

  • Indications: temporary relief of minor aches and pains of muscles and joints (backache, arthritis, strains, bruises, sprains).

  • Format: 50ml (1.7 fl oz) under NDC 48256-0041-1; label revised October 2023.

  • Target customer: North American OTC pain-relief consumers.

  • Labeler/manufacturer: Hoe Hin Pak Fah Yeow Manufactory Ltd.

Hoe Hin White Flower ointment

  • Description: Ointment format of the White Flower brand; historically advertised alongside the oil (1983 advertisement in HK Memory archive; Yahoo Finance company profile references ointments).

  • Specifications, launch year and pricing: not publicly disclosed.

Hoe Hin White Flower Oil Roll-On (planned)

  • Description: Roll-on applicator format announced in the H1 2026 outlook as a planned launch.

  • Target: new consumer groups seeking convenient, less messy application.

  • Launch: planned, timing not specified (Interim Results 2026).

GoodDay essential oil (planned)

  • Description: New essential-oil product announced in the H1 2026 outlook to broaden the portfolio.

  • Target: new consumer groups; positioning appears to extend beyond medicated oils into wellness aromatherapy (analyst inference).

  • Launch: planned, timing not specified (Interim Results 2026).

Advertising agency services

  • Yahoo Finance's company profile lists advertising agency services among group activities; this is not separately disclosed in segment reporting and appears to be an in-house function.

Property Investments segment

AssetTypeValuation 31 Dec 2025 (original currency)Valuation (HKD Mn)FY2025 rent (HKD Mn)Occupancy FY2025
Hong Kong portfolioOffice and residentialHK$102.09 million102.13.4100%
Singapore portfolioIndustrialS$2.434 million14.70.3100%
United Kingdom portfolioRetail/residential (retail tenants include a multinational fast-food chain secured in 2022)GBP10.66 million111.76.2100%

Source: FY2025 Annual Results Announcement; FY2022 Chairman's Statement.

Treasury Investments segment

Bank deposits (HK$331.3 million cash and bank balances at end-FY2025; HK$377.4 million at 30 June 2026), listed equity and debt securities and mutual funds held at fair value through profit or loss (HK$18.1 million at end-FY2025; HK$27.7 million at 30 June 2026), and dual-currency investments.

Financial Narrative

All figures HK$ M, fiscal years ending 31 December. Sources: FY2022, FY2024, FY2025 Annual Results Announcements (audited). Derived metrics are labelled.

Income statement

Derivations: Gross profit = revenue less raw materials and consumables used and changes in inventories of finished goods (excludes production labour and overheads, so it overstates a conventional gross margin). EBITDA = profit from operations before fair value changes plus depreciation; note it includes treasury interest income because the company reports interest as revenue.

Per-share data (HK cents)

Diluted equals basic; there are no dilutive instruments. Weighted shares were 311.64 million in every year.

Margins (%)

Revenue CAGR FY2021–FY2025: 11.2% (HK$139.8 million to HK$213.9 million). Healthcare revenue CAGR: 10.4%. Underlying recurring profit CAGR: 28.4%. These CAGRs are flattered by the depressed COVID-era FY2021 base; FY2023–FY2025 revenue declined at a compound rate of 9.2% a year.

Commentary on the income statement. Three phases are visible. (1) FY2021–FY2022: COVID-constrained recovery, with revenue near HK$140–147 million and operating margins near 32–33%. (2) FY2023: an exceptional surge as the Hong Kong–Mainland border reopened, travellers resumed buying in Hong Kong and Macau, and a wave of purchasing occurred in China; revenue rose 76.1% and operating margin jumped to 55.4%. (3) FY2024–FY2025: normalisation, with China healthcare revenue down 17.2% and then 11.4%, though management said FY2025 Mainland sales met the original full-year target. Through this decline the group protected margins: advertising was cut 28% in FY2025 (HK$14.1 million to HK$10.2 million), helping keep EBITDA margin flat at 55.2%. The divergence between underlying recurring profit and reported profit is driven by property revaluations: cumulative investment-property fair value losses over FY2022–FY2025 were HK$55.6 million, plus a further HK$97.6 million of OCI revaluation deficits on self-use properties in FY2024–FY2025. The lower FY2025 effective tax rate (15.0% vs 19.6%) reflects smaller non-deductible revaluation losses.

Balance sheet

Net debt = bank borrowings less cash and bank balances (excludes FVPL securities and trademark payable). The nature of the long-term deferred income balance (HK$43.4 million at end-FY2025) is not explained in the results announcements and should be checked against the full annual report.

At 30 June 2026 (unaudited): total assets HK$878.3 million; cash HK$377.4 million; FVPL HK$27.7 million; bank borrowings HK$4.9 million; dividends payable HK$35.3 million; equity HK$734.0 million; NAV per share HK$2.36 (Interim Results 2026).

Commentary. The balance sheet is conservatively, arguably excessively, capitalised. Cash rose for four consecutive years to HK$331 million (40% of total assets) despite record dividend payouts. Gearing has been below 1% since FY2022, after management repaid most of its GBP loan in H2 2022 in anticipation of rate rises. Equity has been flat around HK$707–765 million for five years because special dividends and OCI property write-downs have offset retained earnings.

Cash flow

FY2025 capex (additions to non-current assets) was HK$0.4 million. The FY2025 increase in cash of HK$55.4 million despite roughly HK$57.7 million of dividends paid implies operating cash generation above HK$100 million (analyst inference, not a reported figure).

Dividends paid derived as prior-year final and special dividends approved and paid during the year plus current-year interim dividends (dividend notes, FY2022, FY2024, FY2025). No shares were purchased, sold or redeemed in any year reviewed.

Ratios

Derivation notes: ROIC = operating profit before fair value changes × (1 − effective tax rate) ÷ (equity + bank borrowings − cash); this includes interest income in the numerator, overstating operating ROIC slightly. Inventory and payable days use cost of inventories; receivable days use trade plus bills receivables over healthcare revenue. Current ratio, gearing and interest coverage are as reported by the company.

Commentary on ratios. Reported ROE of 10–14% understates the franchise's economic returns because roughly 40–45% of equity sits in low-yielding cash and property. Stripping out cash, invested-capital returns exceed 20%. The cash conversion cycle of about 120 days is long for a consumer product, driven by roughly three months of inventory (reflecting batch manufacturing and imported raw materials) and 30–120-day distributor credit terms. Receivable days rose to 48 in FY2024 as a larger share of sales went through credit-term distributors, then eased to 40 in FY2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts/services

Healthcare

Manufacture and sale of Hoe Hin brand of products via Hoe Hin Pak Fah Yeow Manufactory Limited

White Flower Embrocation (various sizes), floral-scented Fuzai 239, Strain Relief pain-relieving oil, ointment; new roll-on and GoodDay essential oil planned

Property Investments

Investment properties held for rental

Hong Kong office and residential; Singapore industrial; UK retail/residential

Treasury Investments

Deposits and financial assets

Bank deposits, listed equity and debt securities, mutual funds, dual-currency investments

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Healthcare revenue (HKD Mn)

133.0139.5245.2217.4197.3

Property Investments revenue (HKD Mn)

6.87.19.69.19.9

Treasury Investments revenue (HKD Mn)

0.00.64.410.36.6

Total revenue (HKD Mn)

139.8147.2259.2236.8213.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Healthcare segment result (HKD Mn)

54.457.4150.6127.8116.8

Property segment result reported (HKD Mn)

6.4-3.8-7.1-18.52.1

Property underlying recurring result (HKD Mn)

5.44.08.37.68.5

Treasury segment result reported (HKD Mn)

1.3-0.35.59.511.4

Treasury underlying recurring result (HKD Mn)

-0.62.14.28.59.2

Unallocated corporate expenses (HKD Mn)

-14.6-14.8-19.6-20.4-22.2

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Healthcare segment margin (%)

40.941.161.458.859.2

Property underlying margin (%)

79.156.485.983.085.3

Healthcare revenue YoY growth (%)

0.04.975.8-11.3-9.2

Property revenue YoY growth (%)

0.05.234.8-5.29.0

Healthcare share of revenue (%)

95.194.794.691.892.3

Property share of revenue (%)

4.84.83.73.84.6

Treasury share of revenue (%)

0.00.41.74.33.1

Segment Assets & Liabilities

SegmentFY2021FY2022FY2023FY2024FY2025

Healthcare segment assets (HKD Mn)

472.5489.7441.7360.3312.8

Property segment assets (HKD Mn)

287.4266.3257.0228.2229.8

Treasury segment assets (HKD Mn)

76.065.7206.7248.6279.2

Revenue by Segment (Half-Yearly)

SegmentH1 2022H1 2023H1 2024H1 2025H1 2026

Healthcare revenue (HKD Mn)

53.1120.9123.486.793.6

Group revenue (HKD Mn)

56.2126.4132.594.7101.0

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

139.8147.2259.2236.8213.9

Raw materials and inventory change (HKD Mn)

29.331.040.332.629.3

Gross profit, derived (HKD Mn)

110.5116.2218.9204.1184.6

Staff costs (HKD Mn)

34.634.644.043.345.6

Other operating expenses (HKD Mn)

23.727.824.428.223.6

of which advertising, promotion and events (HKD Mn)

12.013.210.814.110.2

Depreciation (HKD Mn)

7.27.57.47.45.8

Operating profit before fair value changes (HKD Mn)

44.548.7143.5123.3112.3

EBITDA, derived (HKD Mn)

51.756.2150.8130.7118.1

Fair value change on investment properties (HKD Mn)

1.0-7.8-15.4-26.0-6.3

Fair value change on financial assets (HKD Mn)

2.0-2.51.31.12.1

Profit from operations (HKD Mn)

47.538.4129.498.3108.1

Finance costs (HKD Mn)

0.60.60.60.60.5

Pre-tax income (HKD Mn)

46.937.8128.897.8107.5

Taxation (HKD Mn)

8.77.823.819.116.2

Net income attributable (HKD Mn)

38.230.0105.078.691.3

Underlying recurring profit (HKD Mn)

35.240.2119.1103.695.5

Total comprehensive income (HKD Mn)

55.124.1105.633.748.5

Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

EPS basic, reported (HK cents)

12.39.633.725.229.3

EPS diluted, reported (HK cents)

12.39.633.725.229.3

EPS underlying recurring (HK cents)

11.312.938.233.230.7

Dividends per share total (HK cents)

8.49.120.520.019.0

Net asset value per share (HKD)

2.272.272.462.352.32

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin, derived (%)

79.078.984.586.286.3

Operating margin before FV changes (%)

31.933.155.452.152.5

EBITDA margin (%)

37.038.258.255.255.2

Pre-tax margin (%)

33.625.749.741.350.3

Net margin (%)

27.320.340.533.242.7

Underlying recurring profit margin (%)

25.227.345.943.844.7

Effective tax rate (%)

18.620.718.519.615.0

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (HKD Mn)

837.7823.1907.5843.4828.4

Investment properties (HKD Mn)

285.6264.9255.3227.0228.5

Property, plant and equipment (HKD Mn)

337.1336.2326.6268.7203.1

Cash and bank balances (HKD Mn)

164.7169.4265.5275.8331.3

Financial assets at FVPL, total (HKD Mn)

18.715.917.019.118.1

Inventories (HKD Mn)

15.115.812.212.112.6

Trade and other receivables (HKD Mn)

13.017.527.533.227.2

Short-term debt, secured bank borrowings (HKD Mn)

16.25.54.74.24.8

Long-term debt (HKD Mn)

0.00.00.00.00.0

Trademark consideration payable, long-term (HKD Mn)

2.12.12.12.12.1

Net debt, negative = net cash (HKD Mn)

-148.5-163.9-260.8-271.6-326.5

Goodwill (HKD Mn)

0.00.00.00.00.0

Intangible assets (HKD Mn)

2.52.52.52.52.5

Working capital, net current assets (HKD Mn)

174.7193.9273.1318.4367.3

Deferred income, total (HKD Mn)

39.137.039.340.043.7

Deferred tax liabilities (HKD Mn)

51.252.051.042.332.2

Total liabilities (HKD Mn)

130.0115.9142.3111.4105.6

Shareholders' equity (HKD Mn)

707.7707.2765.2731.9722.7

Cash Flow

MetricFY2021FY2022FY2023FY2024

Operating cash flow, third-party data (HKD Mn)

70.439.9147.979.0

Capex, additions to non-current assets (HKD Mn)

0.80.23.10.9

Free cash flow, derived (HKD Mn)

69.639.7144.878.1

Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid in year, derived (HKD Mn)

20.624.647.767.057.7

Dividends declared for the year (HKD Mn)

26.228.463.962.359.2

Share buybacks (HKD Mn)

0.00.00.00.00.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, on year-end equity (%)

5.44.213.710.712.6

ROE on underlying profit (%)

5.05.715.614.213.2

ROA (%)

4.63.611.69.311.0

ROIC, derived (%)

6.57.123.221.524.1

Current ratio (x)

6.510.87.216.218.4

Debt to equity (%)

2.30.80.60.60.7

Net debt to EBITDA (x)

-2.9-2.9-1.7-2.1-2.8

Interest coverage, company definition (x)

78.675.6233.3211.2205.6

Asset turnover (x)

0.170.180.290.280.26

Inventory days, derived

117119748391

Receivable days, derived

2435344840

Payable days, derived

13791013

Cash conversion cycle, derived (days)

12814799121118

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

China incl. Hong Kong and Macau (HKD Mn)

97.6101.4202.7167.8148.6

Southeast Asia (HKD Mn)

24.126.334.136.635.4

North America (HKD Mn)

10.510.47.311.511.9

Others (HKD Mn)

0.81.41.11.51.4

Region Margins & Growth (%)

RegionFY2022FY2023FY2024FY2025

China growth (%)

3.999.9-17.2-11.4

Southeast Asia growth (%)

9.129.47.3-3.2

North America growth (%)

-1.4-29.658.33.2

Others growth (%)

76.4-22.035.0-3.0

Revenue by Region (%)

RegionFY2021FY2022FY2023FY2024FY2025

China share of healthcare revenue (%)

73.472.782.777.275.3

Southeast Asia share (%)

18.118.913.916.817.9

North America share (%)

7.97.43.05.36.0

Others share (%)

0.61.00.40.70.7

Revenue by Region — China revenue

RegionFY2021FY2022FY2023FY2024FY2025

China revenue (HKD Mn)

101.2105.7210.2179.0157.3

Southeast Asia revenue (HKD Mn)

24.426.735.138.236.9

North America revenue (HKD Mn)

10.510.47.311.911.9

United Kingdom revenue (HKD Mn)

3.03.15.56.16.4

Other regions revenue (HKD Mn)

0.81.41.11.51.4

China operating result (HKD Mn)

38.235.1125.983.186.8

Southeast Asia operating result (HKD Mn)

11.711.819.721.226.5

North America operating result (HKD Mn)

4.44.23.66.45.8

United Kingdom operating result (HKD Mn)

3.7-1.5-3.43.67.0

Locations

LocationFY2021FY2022FY2023FY2024FY2025

Hong Kong office and residential (HKD Mn)

3.63.94.03.23.4

Singapore industrial (HKD Mn)

0.20.20.30.30.3

United Kingdom retail/residential (HKD Mn)

3.03.15.35.66.2

Revenue by Region (Half-Yearly)

RegionH1 2025H1 2026

China (HKD Mn)

67.780.3

Southeast Asia (HKD Mn)

18.013.2

North America (HKD Mn)

0.90.0

Others (HKD Mn)

0.20.1

Share Price History

DatePrice (HKD)Source

26 Apr 2024

about 2.07–2.12 (52-week range 1.24–2.20)

Yahoo Finance

25 Jul 2025

2.47

Stoxray

5 Dec 2025

2.43

Stoxray

27 Feb 2026

2.42

ET Net

20 Jul 2026

2.32 (52-week range 2.24–2.55)

Google Finance

31 Jul 2026

2.31

StockAnalysis

Valuation Snapshot

MetricValueBasis

Market capitalisation

HK$720 million

311.64 million shares × HK$2.31

Enterprise value

About HK$375 million

Market cap − cash HK$331.3 million − FVPL HK$18.1 million + debt HK$4.8 million

P/E, FY2025 reported

7.9x

EPS 29.3 cents

P/E, trailing twelve months to June 2026

7.3x

TTM profit HK$99.0 million (H2 2025 HK$51.6 million + H1 2026 HK$47.4 million)

P/E, FY2025 underlying

7.5x

Underlying EPS 30.7 cents

EV/EBITDA, FY2025

3.2x

EBITDA HK$118.1 million

EV/Sales, FY2025

1.8x

Revenue HK$213.9 million

P/B

0.98x

NAV HK$2.36 at 30 June 2026

Dividend yield, FY2025

8.2%

19.0 cents

Dividend yield, trailing declared

8.7%

11.0 cents final+special FY2025 + 9.0 cents interim 2026

Components

ComponentFY2021FY2022FY2023FY2024FY2025

Interim dividend incl. special interim (HK cents)

2.82.38.59.58.0

Final dividend (HK cents)

3.83.83.83.83.8

Special final dividend (HK cents)

1.83.08.26.77.2

Total DPS (HK cents)

8.49.120.520.019.0

Payout on reported EPS (%)

68.394.860.879.464.8

Payout on underlying EPS (%)

74.370.553.760.261.9

Analyst Conclusions

Management guidance (H1 2026 Interim Results, August 2026)

Cautious. Management expects continued headwinds from geopolitical tensions, energy price volatility, tariffs and cautious consumers. It considers the China improvement encouraging but uncertain in durability, expects core product sales to fluctuate modestly, expects new products and centenary campaigns to support demand, anticipates the deferred Philippine orders in H2 2026, and expects US orders to resume, keeping full-year North American revenue broadly stable. No quantitative guidance is given.

Consensus growth expectations

Not available — no broker coverage.

Bull case

  1. Earnings have bottomed and are turning: H1 2026 revenue +6.7%, healthcare segment profit +14.7% and margin up to 64.2%; deferred Philippine and US orders should add to H2 2026, and Macau has normalised.

  2. Deep value with downside protection: EV of about HK$375 million is only 3.2x FY2025 EBITDA; cash and securities of about HK$350 million cover roughly half the market cap, the stock trades near book, and the dividend yield exceeds 8%.

  3. Centenary plus digital catalysts: The 2027 centenary campaign, two new product launches and maturing e-commerce and KOL programmes could re-rate a brand starting from an online base below 3% of sales.

Bear case

  1. Structural brand erosion: China healthcare revenue fell 26.7% from FY2023 to FY2025; the core consumer is ageing and competitors and online-native brands are capturing younger buyers, while the company spends only about HK$10 million a year on advertising.

  2. Concentration and fragility: Five distributors control about 75% of healthcare revenue, and H1 2026 showed how a single supplier delay, licence renewal or tariff decision can erase a region's sales.

  3. Capital trapped in low-return assets and governance drag: Falling deposit rates are eroding treasury income, Hong Kong property continues to lose value (HK$93 million OCI deficits in two years), and a family-controlled board with no buybacks and no growth M&A limits the path to unlocking value.

Catalysts and monitorables (next 12 months)

MonitorableTimingWhat to watch
Interim dividend payment4 Dec 2026Confirms payout
Thailand licence renewal and packaging changesQ4 2026Distributor restocking or further destocking
US distributor order resumptionH2 2026Whether North America revenue is "broadly stable" for FY2026
Philippine deferred shipmentsH2 2026Southeast Asia recovery
Roll-On and GoodDay launches2026–2027Launch timing and early traction
Centenary campaign2,027Brand reach; advertising spend level
FY2026 annual resultsLate March 2027Healthcare growth, margin, special dividend
Year-end property valuationsDec 2026Hong Kong office values; further OCI deficits
Interest ratesOngoingTreasury income trajectory
Succession and governanceOngoingAny CEO succession plan; role of Gavin/Gary Gan; board refresh
Capital allocationOngoingAny buyback, larger special dividend or acquisition

Analyst verdict

Pak Fah Yeow International is a high-quality franchise housed inside an under-optimised holding company. The economics of the Hoe Hin White Flower business are genuinely excellent: a near-century-old brand earning segment margins near 60%, requiring negligible capital expenditure and generating cash far in excess of what the business can absorb. That cash has accumulated into roughly HK$350 million of deposits and securities alongside an HK$228 million property portfolio, so that the market effectively values the operating franchise at only about three times EBITDA.

The past three years have tested the franchise. The 2023 reopening boom flattered results, and the subsequent normalisation revealed concentration risks — dependence on China, on five distributors and on licence and supply-chain events — that the company is only beginning to address. Encouragingly, the first half of 2026 marked a return to growth with expanding margins, and management is finally investing in the channels where the next generation of consumers shops: Douyin, Xiaohongshu, KOLs and cross-border e-commerce. The centenary in 2027 and two new product formats give the brand its best opportunity in years to reach younger buyers.

The case against is structural rather than financial. A single traditional formula with an ageing consumer base faces gradual erosion, advertising spend remains modest, governance is family-dominated with a combined Chairman/CEO aged about 80, and there is no visible plan to redeploy surplus capital through buybacks or brand acquisitions. Property revaluations will continue to cloud reported earnings.

The key swing factors over the next twelve months are the durability of China's recovery, resolution of US tariff-related ordering, and evidence that the June 2026 succession step translates into a more dynamic capital-allocation strategy.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleBoard tenure / key datesBackgroundAge (est.)

Gan Wee Sean (顏為善)

Executive Director, Chairman and CEO; Remuneration Committee member

ED since 8 Oct 1991; acting CEO 21 Apr 2008; CEO since 1 Sep 2011

Grandson of founder Gan Geok Eng; born Penang 1946; studied management in the UK; joined HK HQ in 1971; led the 1991 restructuring and listing. Fellow of the Institute of Chartered Secretaries and Administrators and of the Chartered Institute of Marketing; former chairman of the Chung Sing Benevolent Society (1987–1990) and of the Malaysian Association in Hong Kong (1987–1989)

About 80 (born 1946)

Gan Fock Wai, Stephen (顏福偉)

Executive Director; Remuneration Committee member

ED for 20+ years; was CEO around 2005–2006

Family member; director of Gan's Enterprises Limited, a substantial shareholder (per 2006 report)

About 65 (aged 45 in 2006)

Gan Cheng Hooi, Gavin (顏清輝)

Executive Director

—

Son of Gan Wee Sean; now a co-owner of Hexagan Enterprises following the June 2026 transfer

—

Gan Fook Yin, Anita (顏福燕)

Non-executive Director; Nomination Committee member

Nomination Committee since Dec 2023

Family member

—

Leung Man Chiu, Lawrence (梁文釗)

Independent Non-executive Director; Chairman of Audit, Nomination and Remuneration Committees

———

Chan Chi Chung, Simon (陳志冲)

INED; member of all three committees

Joined 2022

Consultant at a leading Hong Kong law firm with broad legal-sector experience (FY2022 Chairman's Statement)

—

Dell'Orto Renato

INED; member of all three committees

Joined 2022

Extensive experience in healthcare-sector supply chain management and market expansion (FY2022 Chairman's Statement)

—

“—” = not publicly disclosed.

Directors' Remuneration

DirectorFeesSalary and benefitsBonusRetirementTotal FY2023

Gan Wee Sean (Chair/CEO)

486,5651,234287,875

Gan Fock Wai, Stephen (ED)

484,5211,1865996,354

Gan Cheng Hooi, Gavin (ED)

1561,485476182,135

Gan Fook Yin, Anita (NED)

151000151

Leung Man Chiu, Lawrence (INED)

151000151

Chan Chi Chung, Simon (INED)

151000151

Dell'Orto Renato (INED)

151000151

Governance Overview

MetricValue

Board size

7

Executive directors

3 (all Gan family)

Non-executive (non-independent)

1 (Gan family)

Independent non-executive

3 (43%) — meets the HKEX one-third minimum

Family directors

4 of 7 (57%)

Women on board

1 of 7 (14%)

Chair/CEO separation

No — combined since 2011; disclosed deviation from CG Code provision C.2.1

Audit Committee

3 INEDs; meets at least twice a year

Committee chairs

One INED (Leung) chairs all three committees

Major Shareholders

HolderShares (M)%Source

Hexagan Enterprises Limited (now owned by the four children of Gan Wee Sean: Gary Gan, Gavin Gan and two sisters)

65.3220.96

Voluntary announcement, 30 Jun 2026

Gan Wee Sean (direct)

27.218.73

Same

Madam Khoo Phaik Gim (spouse)

2.380.76

Same

Gan Family Group subtotal

94.9130.46

Same

Competitive Landscape

Key Competitors

CompetitorOwnerKey brandsMarketsNotes

Haw Par Corporation (SGX: H02)

Listed, Singapore

Tiger Balm, Kwan Loong

100+ countries; ASEAN core

Closest listed peer; similar holding-company structure with large investment portfolio

Kwan Loong Medicated Oil

Haw Par

Kwan Loong

Singapore, Malaysia, Hong Kong

Direct medicated-oil rival; part of Haw Par Healthcare segment

Axe Brand Universal Oil

Leung Kai Fook Medical Co.

Axe Brand

Hong Kong, China, SEA

Direct medicated-oil rival

Eagle Brand Medicated Oil

Borden Company (Singapore; private)

Eagle Brand (green oil)

SEA, Hong Kong

Direct rival

Lion King Oil

—

Lion King

Hong Kong

Direct rival in HK

Zihua Embrocation

—

Zihua

Hong Kong

Positioned for consumers averse to pungent smells — competes with Fuzai 239

Po Sum On

Po Sum On Medicine Factory (Hong Kong; private)

Po Sum On oil

Hong Kong, overseas Chinese

Direct rival

Wong To Yick Wood Lock Medicated Balm

Hong Kong (private)

Wood Lock oil

Hong Kong, China

Pain-relief oil rival

Mentholatum

Rohto Pharmaceutical (Japan, listed)

Mentholatum ointments

Asia

Adjacent topical category

Salonpas

Hisamitsu Pharmaceutical (Japan, listed)

Salonpas patches and sprays

Asia, US

Adjacent topical analgesic category

Zheng Gu Shui

Guangxi Yulin Pharmaceutical (China)

Zheng Gu Shui

China, overseas Chinese

Traditional Chinese topical analgesic

Mainland "feng you jing" producers

Various Chinese manufacturers

Generic medicated oils

Mainland China

Low-price competition

Peer Comparison FY2025

MetricPak Fah Yeow FY2025Haw Par FY2025

Group revenue

HK$213.9 million

S$230.0 million (approx. HK$1.4 billion)

Healthcare revenue

HK$197.3 million

S$210.4 million per Haw Par Annual Report 2025 (one third-party source cites S$240.5 million — discrepancy noted; S$210.4 million is consistent with group revenue of S$230.0 million)

Healthcare revenue growth

-9.2%-7%

Healthcare segment profit

HK$116.8 million

S$67.1 million (+7%)

Healthcare segment margin

59.2%

About 32% (S$67.1 million / S$210.4 million)

Net profit

HK$91.3 million

S$265.5 million (+16.3%, driven by dividend income)

Net cash

About HK$326 million

About S$791 million cash

Company Snapshot

$27.5M

Revenue

100

Employees

$92M

Market Cap

1927

Founded

Wan Chai, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Exceptional segment profitability: Healthcare segment margin of 59.2% in FY2025 and 64.2% in H1 2026 (FY2025 and Interim 2026 results), versus about 32% for Haw Par's healthcare segment.
  • Fortress balance sheet: HK$331.3 million cash at end-FY2025 (HK$377.4 million at 30 June 2026) against only HK$4.8 million of bank debt; gearing 0.7% and current ratio 18.4x (FY2025).
  • Heritage brand with century-long equity: Created in 1927, trademark registered 1935, named a Hong Kong Top Ten Brand in 1999 (Annual Report 2000; HK Memory Project).
  • Generous, consistent shareholder returns: DPS of 20.5, 20.0 and 19.0 HK cents for FY2023–FY2025, equal to 61–79% of reported EPS, plus H1 2026 interim up 12.5% to 9.0 cents.
  • Minimal capital intensity: Additions to non-current assets of HK$0.4 million in FY2025 against EBITDA of HK$118.1 million.
  • Margin resilience under revenue pressure: Healthcare revenue fell 19.5% from FY2023 to FY2025, yet segment margin moved only from 61.4% to 59.2%.
  • Diversified recurring rental income: All three property portfolios 100% occupied in FY2025 and H1 2026; underlying property result up 12.0% to HK$8.5 million.

Weaknesses

  • Customer concentration: Five distributors generated HK$147.0 million, 74.5% of healthcare revenue, in FY2025 (note 2).
  • Geographic concentration: China (incl. HK and Macau) accounted for 75.3% of healthcare revenue in FY2025.
  • Single-brand dependency and thin innovation: No disclosed R&D spend; portfolio essentially one formula plus fragrance and format variants.
  • Weak online presence: Online sales below 3% of total revenue in FY2024, as the company itself acknowledged.
  • Governance: Combined Chair/CEO (C.2.1 deviation), four of seven directors from the Gan family, one INED chairing all three committees, CEO aged about 80.
  • Capital inefficiency: Cash and securities of about HK$350 million (roughly half of market cap) earning falling deposit yields; reported ROE of 12.6% in FY2025 vs ROIC above 20% ex-cash.
  • Supply-chain fragility: A single late packaging-material delivery cut H1 2026 Southeast Asia revenue by 26.8%.

Opportunities

  • E-commerce and cross-border channels: Launched in 2025; from a base below 3% of revenue, even modest penetration offers growth.
  • Brand rejuvenation through content platforms: Douyin, Xiaohongshu and KOL programmes target younger consumers.
  • Centenary marketing (2027): 100th-anniversary campaigns provide a natural brand-relaunch moment.
  • Product extensions: Roll-On and GoodDay essential oil open convenience and wellness/aromatherapy adjacencies.
  • Southeast Asia and North America growth: North America grew 58.3% in FY2024 after capacity expansion; Philippines demonstrated strong growth.
  • Capital redeployment: HK$350 million of surplus liquidity could fund buybacks, larger special dividends or bolt-on brand acquisitions (no plans announced).
  • Recovery of Mainland visitor traffic to Hong Kong and Macau: Macau normalisation already lifted H1 2026 China revenue by 18.6%.

Threats

  • US trade policy: Tariff uncertainty led to zero North American revenue in H1 2026.
  • Hong Kong property values: HK investment property valuation fell from HK$149.1 million (FY2021) to HK$102.1 million (FY2025); self-use property deficits of HK$93.1 million in OCI over FY2024–FY2025.
  • Falling interest rates: Treasury revenue down 35.5% in FY2025 and 29.7% in H1 2026.
  • Competition from scaled and cheaper rivals: Haw Par (Tiger Balm, Kwan Loong) and low-priced Mainland medicated oils.
  • Regulatory licence renewals: Macau renewal caused 2024–25 demand volatility; Thailand renewal with possible packaging changes due Q4 2026.
  • Geopolitics and energy: Management flagged Middle East conflict impacts on energy prices, FX and consumer sentiment (FY2025 and H1 2026 outlooks).
  • Demographic erosion: Category associated with older consumers; ageing core buyer base.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 Mar 2025FY2024 results: revenue -8.6% to HK$236.8 million; reported profit -25.1% to HK$78.6 million; underlying -13.0% to HK$103.6 millionConfirmed post-reopening normalisation (window context)
27 Mar 2025FY2024 final 3.8 cents + special final 6.7 cents proposed (total year 20.0 cents)Payout maintained despite profit fall
27 Mar 2025Management flags US tariff risk and pivots China strategy to e-commerceStrategic shift
16 Jun 2025AGM approves FY2024 dividendsRoutine
Jul 2025Ex-dividend and record date (11 Jul 2025) for FY2024 final dividendsRoutine
8 Aug 2025FY2024 final and special dividends paidCash return HK$32.7 million
21 Aug 2025H1 2025 results: revenue -28.5% to HK$94.7 million; reported profit -16.2% to HK$39.7 million; underlying -26.6%Trough of the cycle; Macau destocking
21 Aug 2025Interim 3.0 cents + special interim 5.0 cents declaredSpecial cut from 6.5 cents
18 Sep 2025Interim Report 2025 publishedDisclosure
29 Sep 2025Ex-dividend date for 2025 interim dividends (TipRanks)Routine
During 2025Cross-border e-commerce operations launchedNew channel
During 2025Increased Douyin/Xiaohongshu advertising and KOL collaborationBrand rejuvenation
During 2025Hong Kong investment properties return to 100% occupancy (from 79.5%)Rental recovery
During 2025Philippines warehouse inventory rebalancing reduces shipmentsTemporary SEA drag
30 Mar 2026FY2025 results: revenue -9.7% to HK$213.9 million; reported profit +16.2% to HK$91.3 million; underlying -7.8% to HK$95.5 millionRevaluation losses narrow sharply
30 Mar 2026Final 3.8 cents + special final 7.2 cents proposed; FY2025 total 19.0 centsSpecial dividend raised vs prior year
30 Mar 2026Outlook cites Middle East conflict, energy prices and FX volatility as new risksRisk escalation
30 Mar 2026FY2025 OCI revaluation deficit of HK$50.2 million on self-use propertiesNAV pressure
2 Jun 2026AGM approves FY2025 final and special dividendsRoutine
30 Jun 2026Hexagan ownership transferred to Gan Wee Sean's four childrenSuccession of controlling vehicle
6 Jul 2026Ex-dividend date for FY2025 final dividends (Google Finance)Routine
31 Jul 2026Positive profit alert: H1 2026 profit expected around HK$47.4 millionSignals return to growth
7 Aug 2026FY2025 final and special dividends paid (HK$34.3 million)Cash return
20 Aug 2026H1 2026 results: revenue +6.7% to HK$101.0 million; reported profit +19.1% to HK$47.4 million; underlying +3.7% to HK$47.0 millionFirst growth since H1 2024
20 Aug 2026China healthcare revenue +18.6% to HK$80.3 million on Macau normalisationKey recovery driver
20 Aug 2026Southeast Asia -26.8% due to late supplier delivery of packaging (Philippines), Thai destockingSupply-chain vulnerability
20 Aug 2026No North American revenue in H1 2026 as the US distributor paused orders on tariffsTariff impact materialised
20 Aug 2026Roll-On and GoodDay essential oil launches and 100th-anniversary campaigns announcedProduct/brand initiatives
20 Aug 2026Interim 3.0 cents + special interim 6.0 cents declared (+12.5%)Higher payout
20 Aug 2026UK banking facility shown as HK$9.4 million (vs HK$57.0 million reported at Dec 2025 in the annual results; the interim restates Dec 2025 as HK$10.2 million)Facility apparently resized; discrepancy between documents
2–6 Oct 2026Register closed; record date 6 Oct 2026 for interim dividendsRoutine
4 Dec 2026 (scheduled)Payment of 2026 interim dividends (HK$28.0 million)Upcoming

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

9 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 139.8 Mn in FY2021 to HKD 213.9 Mn in FY2025.
Pak Fah Yeow International Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue139.8147.2259.2236.8213.9
Gross profit110.5116.2218.9204.1184.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Pak Fah Yeow International — Announcement of Annual Results 2025 (30 Mar 2026) (www1.hkexnews.hk)
  2. Pak Fah Yeow International — Interim Results Announcement H1 2026 (20 Aug 2026) (www1.hkexnews.hk)
  3. Pak Fah Yeow International — Positive Profit Alert (31 Jul 2026) (www1.hkexnews.hk)
  4. Pak Fah Yeow International — Announcement of Annual Results 2024 (27 Mar 2025) (www1.hkexnews.hk)
  5. Pak Fah Yeow International — Announcement of Annual Results 2022 (30 Mar 2023) (www1.hkexnews.hk)
  6. Pak Fah Yeow International — Announcement of Annual Results 2023 (26 Mar 2024) (www1.hkexnews.hk)
  7. Pak Fah Yeow International — Interim Results H1 2025 (21 Aug 2025) (www1.hkexnews.hk)
  8. Pak Fah Yeow International — Interim Report 2025 (hkexnews.hk)
  9. Pak Fah Yeow International — Interim Report 2022 and 2023; Annual Reports 2000, 2005, 2006, 2021, 2022, 2023 (HKEXnews)
  10. Pak Fah Yeow International — List of Directors and their Role and Function (30 Sep 2022; 7 Dec 2023)
  11. Bulletin Express via Tiger Brokers — Hexagan restructuring (30 Jun 2026) (itiger.com)
  12. Bulletin Express via Tiger Brokers — FY2025 results summary (itiger.com)
  13. Hong Kong Memory Project — Hoe Hin Pak Fah Yeow company history and Gan Wee Sean oral history · hkmemory.hk
  14. HKEX Disclosure of Interests filing (Jan 2014) (di.hkex.com.hk)
  15. Webb-site Reports — Pak Fah Yeow directors' pay FY2023 (webb-site.com)
  16. StockAnalysis — 0239 income statement (stockanalysis.com)
  17. Stoxray — 0239 profile (stoxray.com)
  18. TipRanks — 0239 statistics and news (tipranks.com)
  19. Simply Wall St — 0239 management (simplywall.st)
  20. Google Finance — 0239:HKG (google.com)
  21. Yahoo Finance — 0239.HK (finance.yahoo.com)
  22. ET Net — 00239 financial summary (etnet.com.hk)
  23. Mannings / Watsons product listings; OTCLabels.com (White Flower Strain Relief)
  24. Localiiz — Guide to eastern medicated oils in Hong Kong (localiiz.com)
  25. Haw Par Corporation Annual Report 2025 (SGX); The Edge Singapore FY2025 results article; Beansprout Haw Par initiation (July 2026)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.